1 published article · Updated continuously
20 trials tracked for Cervical dystonia: 12 in phase 3 or 4 and 5 with published results. The most-cited published study has 44 citations.
Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Multiple trials demonstrate that botulinum toxin type A (BTX-A) is effective in reducing symptoms of cervical dystonia. Significant improvements were observed in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total scores across several studies, including a reduction of 12.46 to 13.99 points 6 and consistent reductions over multiple treatment cycles 9. Specific subscale improvements in severity and disability were also noted following BTX-A administration [6, 11, 12].
Specific formulations of botulinum toxins have shown efficacy; Xeomin (incobotulinumtoxinA) demonstrated significant reductions in TWSTRS total scores at week 4 compared to placebo for both 120 and 240 unit doses 10, with no significant difference between the two dosages 10. Dysport (abobotulinumtoxinA) also showed a reduction in TWSTRS total scores 3. Botulinum toxin type B was evaluated in separate trials, showing improvements in TWSTRS total, functional disability, and pain subscales 15.
Experimental treatments such as ABP-450 showed measurable changes in TWSTRS total scores and associated subscales for severity, disability, and pain [13, 14]. In contrast, repetitive transcranial magnetic stimulation (rTMS) did not produce statistically significant changes in TWSTRS scores or related measures like the Beck Depression Inventory or Trail-Making Test in a small cohort 17.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
